The following AEs occurred more often among patients who received BLV 2 mg (n = 64)—the approved dosage for treatment of CHD in adults with compensated liver disease [14]—compared to controls: total bile acids increased (13 patients, 20%), ISRs (10 patients, 16%), headache (10 patients, 16%), pruritus (7 patients, 11%), eosinophilia (6 patients, 9%), neutropenia (5 patients, 8%), ALT increased, (5 patients, 8%) and fatigue (6 patients, 9%). Here, GPT is linked to neutropenia.